Merkel Cell Carcinoma (MCC) is an uncommon but highly malignant skin cancer originating from Merkel cells in the epidermis. Strongly associated with the Merkel cell polyomavirus (MCPyV), present in around 80% of cases, MCC typically affects older adults and those with compromised immune systems. Recent strides in cancer research have led to promising immunotherapies, including checkpoint inhibitors, which enhance the immune system's ability to identify and eradicate cancer cells. Early diagnosis is critical due to MCC's propensity for rapid metastasis, complicating treatment. Research efforts continue to focus on unraveling the molecular underpinnings of MCC, with the goal of developing more effective therapeutic strategies and improving patient survival rates.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China